offline
Gilead Sciences (GILD) Misses Q4 Earnings Estimates
Gilead Sciences (GILD) came out with quarterly earnings of $1.30 per share, missing the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $1.44 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -22.62%. A quarter ago, it was expected that this HIV and hepatitis C drugmaker would post earnings of $1.76 per share when it actually produced earnings of $1.75, delivering a surprise of -0.57%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Gilead, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $5.88 billion for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 2.68%. This compares to year-ago revenues of $5.80 billion.
...
https://finance.yahoo.com/news/gilead-sc...10563.html
![[Bild: GILDc1dl0608.png]](https://finviz.com/publish/020520/GILDc1dl0608.png)
Gilead Sciences (GILD) came out with quarterly earnings of $1.30 per share, missing the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $1.44 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -22.62%. A quarter ago, it was expected that this HIV and hepatitis C drugmaker would post earnings of $1.76 per share when it actually produced earnings of $1.75, delivering a surprise of -0.57%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Gilead, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $5.88 billion for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 2.68%. This compares to year-ago revenues of $5.80 billion.
...
https://finance.yahoo.com/news/gilead-sc...10563.html
__________________
